ABSTRACT

We discuss the case of a 17-year-old male who at the age of 7 was diagnosed with celiac disease (CD) together with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). The patient was treated with a gluten-free diet and immunosuppressive drugs (azathioprine), and currently remains asymptomatic.

The patient’s younger, 12-year-old sister was diagnosed with CD when she was 1.5 years old, and at 7 years she developed type-I diabetes mellitus, which was difficult to control.

A family study was made, and both parents were found to be affected with silent CD. All were DQ2 (+). In relation to the case and family study, we provide a series of comments related to CD and its complications.

Key words: Celiac disease (CD). Ulcerative colitis (UC). Primary sclerosing cholangitis (PSC). Family study.

INTRODUCTION

Celiac disease (CD) is a process which presents in genetically predisposed individuals—generally HLA-DQ2 (+) in around 90% of cases or HLA-DQ8 (+) in the remaining 7-10% of cases—as a consequence of an altered immune response to an extrinsic factor, namely gliadin, a protein contained in the flour of most cereals except corn.

In CD patients it is relatively frequent to find the presence of associated diseases such as type I diabetes, herpetiformis dermatitis, and autoimmune thyroiditis, among others (1-3).

The finding of moderate familial aggregation in patients with CD is normal. This ranges from 10% to 20% of cases (4), and family members may be asymptomatic or have atypical forms resulting in no search for cases, thus remaining undiagnosed for long periods of time.

Primary sclerosing cholangitis (PSC) is a liver disease of autoimmune nature in which genetic, acquired, or both factors are involved. Its association with other diseases is well demonstrated, most commonly including inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) in 70% of cases.

We present the case of a patient with CD associated with UC and PSC, all of which began in infancy, and in whose family study we found different presentation forms together with other associated diseases in the father and a sister, both of them affected.

CASE STUDY

A 17-year-old patient who was initially referred to our center from a local hospital some 10 years ago, at the age of 7, because of a persistent alteration of liver function tests for one year then.

His parents reported the existence of various intermittent diarrhea episodes since 6 months of age, which had been classified as irritable bowel syndrome (IBS).

No previous history of blood transfusions, episodes of acute hepatitis, jaundice, or pruritus were reported. Physical examination was negative, and the patient had a normal development for his age.
A CBC was normal, and liver function tests showed a mixed pattern of cytolysis plus dissociated cholestasis, with AST = 133 (n < 40) IU/L; ALT = 211 (n < 40) IU/L; AP = 1.365 (n < 180) IU/L; GGT = 268 (n < 50) IU/L; total bilirubin = 2.2 (n < 1) mg/dl.

The screening for the various viral markers of hepatitis (A, B, C, CMV, EB, HS and VZ), and anti-toxoplasm antibodies were all negative. Non-organ specific auto-antibodies (ANAs, AMAs, AML, and anti-LKM1), and the early detection of metabolic disease (hemochromatosis, Wilson’s disease, α1-antitripsin deficiency) were also negative.

Laboratory studies showed the presence of ANAs (+) at low titres (1/40); EMAs (+) (1/80); anti-reticulin antibodies (+) (1/160), and p-ANCA (+) (1/320), all at medium-high titres. The remaining laboratory tests were normal.

For the study of diarrhea and the presence of positive serological markers of CD, an intestinal biopsy with a Watson-Crosby capsule was made. The histological study showed the presence of severe duodenal villi atrophy, with crypt hypertrophy together with the presence of severe lymphocytic infiltration in the submucosa, thus confirming the diagnosis of CD classified as Marsh stage 3c (Fig. 1A).

A sigmoidoscopy was performed and demonstrated the presence of a friable, edematous mucosa which bled easily on contact with the endoscope, multiple erosions, and superficial ulcerations. Colonic biopsies demonstrated the presence of chronic inflammatory infiltration of the submucosa, with the presence of crypt abscesses and epithelial erosions, this being diagnosed as moderate UC (Fig. 1B).

A liver biopsy was performed, in which the presence of a moderate portal and lobulillar inflammatory infiltrate with severe porto-portal and periductular fibrosis in the form of “onion layers” was seen, together with intense ductular proliferation, this being diagnosed as PSC (Fig. 1C).

In order to make a topographic diagnosis and for extension assessment an endoscopic retrograde cholangiopancreatography (ERCP) was made, which showed the presence of an intrahepatic “winter aspect” of the biliary tree in the canalicular branches, and with “beaded ducts”, together with a preserved extra-hepatic duct, thus confirming a predominance of intrahepatic involvement.

The patient was started on a gluten-free diet (GFD) and received ursodeoxycholic acid (900 mg/day) and 5-ASA (2 g/day). He remained asymptomatic, with improved liver function tests, for 2 years. The patient later presented with an episode of acute cholangitis, which responded favourably to antibiotic treatment at home, and a relapse of UC, which required admittance to hospital; azathioprine (150 mg/day) was then initiated, which is currently maintained. Two years ago, an upper GI endoscopy was performed and showed normal findings. Duodenal biopsies were made and were normal.

The patient is currently completely asymptomatic, living a normal life, and attending our outpatient clinic every 6 months.

**FAMILY STUDY**

One year after the index case was diagnosed, his younger sister, at 1.5 years of age, presented with diarrhea, abdominal pain, and vomiting, together with weight loss and growth retardation. Serological studies and jejunal biopsies were made, and the diagnosis of celiac disease (CD) in its classical form was confirmed; duodenal biopsies showed a moderate degree of atrophy (Marsh’s stage 3b). A GFD was begun and a good clinical-laboratory response was seen. Six years later, at the age of 7.5 years, this patient presented with type I diabetes mellitus,
which proved difficult to control. Three daily doses of rapid insulin are required for adequate control.

With these findings in a brother and sister, a family study was begun. Both were completely asymptomatic. Laboratory-wise, the mother had slight sideropenia. The father had normal laboratory tests, with a positive serological profile for CD and moderate duodenal villi atrophy (Marsh’s stage 3b). Both were diagnosed with silent CD and started on a GFD. They continue to be asymptomatic without associated diseases, and do not currently show any laboratory changes. The findings in the family, laboratory, genetic, and histological studies show that all members of this family were affected, all four of them being DQ2 (+). The mother had a negative serology for CD, and showed no signs of villous atrophy at the duodenal biopsy, only a mild inflammatory infiltrate of the submucosa (Marsh’s stage 2) (Table I).

DISCUSSION

The association between UC and PSC is well documented, and it is estimated that 3-5% of patients with UC may develop PSC along their lives (4).

However, the association between CD and PSC is much lower, with an estimated mean frequency of around 1.5% (5).

An association between CD and autoimmune chronic cholestatic liver diseases such as primary biliary cirrhosis (PBC) and autoimmune cholangitis (AIC), which presents with an intermediate frequency between the above-mentioned figures, exists and is estimated to be around 3.5% of cases (6).

Only a few cases have been described thus far on this rare association between CD, UC and PSC. In the majority of cases UC precedes by several years the diagnosis of the other two diseases; this is different in our case, as the three conditions were diagnosed virtually simultaneously.

For this reason, above all in patients with CD, we recommend the use of an active search for associated diseases, not only digestive but also systemic conditions. This appears to be due to the fact that various processes share the same HLA class II haplotype, which could probably be the main predisposing factor for the development of other comonitant diseases autoimmune in nature (7,8).

It has been speculated whether the delay in making the diagnosis of CD and therefore in the initiation of a gluten-free diet (GFD) may favour the appearance of associated diseases, although this hypothesis is highly controversial and at present has not been clarified (9,10).

A study carried out with the aim of estimating the prevalence of CD in children and young people with type-I diabetes mellitus and the influence of its early diagnosis in the prevention of a later development of CD,

---

Table I. Demographic, clinical, laboratory, serologic, genetic, and pathological characteristics of the family study

<table>
<thead>
<tr>
<th>Family relationship</th>
<th>Age/gender</th>
<th>Clinical</th>
<th>Biochemical</th>
<th>Serological</th>
<th>HLA</th>
<th>Intestinal biopsy</th>
<th>Marsh stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index case</td>
<td>7/M</td>
<td>Diarrhea</td>
<td>Hypertransaminasemia</td>
<td>AGA (−)</td>
<td>DQ2 (+)</td>
<td>Subtotal atrophy</td>
<td>(3c)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AEM 1/80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AR 1/160</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sister</td>
<td>1.5/F</td>
<td>Abdominal pain</td>
<td>Normal</td>
<td>AGA 1/68</td>
<td>DQ2 (+)</td>
<td>Moderate atrophy</td>
<td>(3b)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weight loss</td>
<td></td>
<td>AEM 1/320</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AR 1/320</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Father</td>
<td>41/M</td>
<td>Asymptomatic</td>
<td>Normal</td>
<td>AGA 42</td>
<td>DQ2 (+)</td>
<td>Moderate atrophy</td>
<td>(3b)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AEM 1/320</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mother</td>
<td>42/F</td>
<td>Asymptomatic</td>
<td>Ferropenia</td>
<td>AGA (−)</td>
<td>DQ2 (+)</td>
<td>Submucosal infl. infiltrate</td>
<td>(2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AEM (−)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

M: male; F: female; AGA: anti-gliadin Ab; AEM: anti-endomysium Ab; AR: anti-reticulin Ab.
showed that the prevalence of this association is 7%, and the diagnosis of type-1 diabetes mellitus at an early age (< 4 years), and the fact of being female, are associated with a greater risk of having both diseases. Several studies also exist that had conflicting results regarding whether the early diagnosis of CD and the starting of a GFD prevents the development of other diseases with an immunological basis (11,12).

In our family, the younger sister was diagnosed at 1.5 years of age with CD, and in spite of a strict GFD she developed type-1 diabetes mellitus after 5 years. All members of this family were HLA-DQ2 (+), and—as is well known—this is a gene not only closely related to the development of CD, but also to the development of type-1 diabetes mellitus (13).

An increased risk of developing malignant neoplasms such as cholangiocarcinoma exists in patients with PSC, and a higher incidence of colon cancer develops in patients with ulcerous pancolitis, especially in cases with severe acute onset, standing for more than 10 years, although recent studies showed a possible prevention of colon cancer in patients treated with ursodeoxycholic acid in the long term (14).

Although the familiar aggregation of CD is 10-20%, in our case all members were affected, two of them with a diagnosis during infancy and with associated diseases, while the parents were diagnosed with silent forms of CD through a family study, and had a good response to GFD (15).

It is important therefore to routinely carry out a family study before making a diagnosis of CD, for the diagnosis of new cases—even if asymptomatic from GFD onset—may prevent the development of complications, and probably the appearance of associated diseases.

REFERENCES